

ENCISION INC
Form 10-Q
February 11, 2014
[Table of Contents](#)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2013

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-11789

ENCISION INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: ENCISION INC - Form 10-Q

Colorado
(State or other jurisdiction of
incorporation or organization)

84-1162056
(I.R.S. Employer Identification No.)

6797 Winchester Circle

Boulder, Colorado 80301

(Address of principal executive offices)

(303) 444-2600

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

Common Stock, no par value
(Class)

10,673,225 Shares
(outstanding at January 31, 2014)

Table of Contents

ENCISION INC.

FORM 10-Q

For the Three Months Ended December 31, 2013

INDEX

	Page Number
<u>PART I.</u>	
<u>FINANCIAL INFORMATION</u>	
<u>ITEM 1</u>	
Condensed Interim Financial Statements:	
Condensed Balance Sheets as of December 31, 2013 and March 31, 2013	3
Condensed Statements of Operations for the Three and Nine Months Ended December 31, 2013 and 2012	4
Condensed Statements of Cash Flows for the Nine Months Ended December 31, 2013 and 2012	5
Notes to Condensed Interim Financial Statements	6
<u>ITEM 2</u>	
Management's Discussion and Analysis of Financial Condition and Results of Operations	10
<u>ITEM 4</u>	
Controls and Procedures	16
<u>PART II.</u>	
<u>OTHER INFORMATION</u>	
<u>ITEM 6</u>	
Exhibits	17
<u>SIGNATURE</u>	18

Table of Contents**PART I** **FINANCIAL INFORMATION****ITEM 1** **CONDENSED INTERIM FINANCIAL STATEMENTS****Encision Inc.****Condensed Balance Sheets****(unaudited)**

	December 31, 2013	March 31, 2013
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1,520,354	\$ 126,224
Accounts receivable, net of allowance for doubtful accounts of \$10,000 at December 31, 2013 and \$9,000 at March 31, 2013	1,060,396	985,770
Inventories, net of reserve for obsolescence of \$80,000 at December 31, 2013 and \$51,000 at March 31, 2013	2,657,050	2,929,302
Prepaid expenses	109,961	65,891
Total current assets	5,347,761	4,107,187
Equipment, at cost:		
Furniture, fixtures and equipment	3,153,737	2,691,057
Customer-site equipment	1,018,054	931,060
Equipment-in-progress	108,591	774,004
Leasehold improvements	319,854	
Accumulated depreciation	(2,782,654)	(2,767,195)
Equipment, net	1,817,582	1,628,926
Patents, net of accumulated amortization of \$209,041 at December 31, 2013 and \$190,770 at March 31, 2013	249,803	237,606
Other assets	13,582	9,215
TOTAL ASSETS	\$ 7,428,728	\$ 5,982,934
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 385,910	\$ 823,347
Accrued compensation	295,946	319,116
Other accrued liabilities	372,320	446,171
Lease payable - short term	60,210	
Deferred rent - short term	30,384	
Total current liabilities	1,144,770	1,588,634
Lease payable - long term	72,014	
Deferred rent - long term	139,260	
Total liabilities	1,356,044	1,588,634
Commitments and contingencies		
Shareholders' equity:		
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding		
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 10,673,225 and 8,210,100 shares issued and outstanding at December 31, 2013 and March 31, 2013, respectively	23,577,078	21,569,993

Edgar Filing: ENCISION INC - Form 10-Q

Accumulated (deficit)	(17,504,394)	(17,175,693)
Total shareholders' equity	6,072,684	4,394,300
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 7,428,728	\$ 5,982,934

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents**Encision Inc.****Condensed Statements of Operations****(Unaudited)**

	Three Months Ended		Nine Months Ended	
	December 31, 2013	December 31, 2012	December 31, 2013	December 31, 2012
NET REVENUE:				
Product	\$ 2,643,757	\$ 2,954,849	\$ 7,851,755	\$ 8,566,008
Service	71,748	99,831	191,063	463,835
Total Revenue	2,715,505	3,054,680	8,042,818	9,029,843
COST OF REVENUE:				
Product	1,245,320	1,316,962	3,635,427	3,691,724
Service	46,670	71,805	118,817	311,572
Total Cost of Revenue	1,291,990	1,388,767	3,754,244	4,003,296
GROSS PROFIT	1,423,515	1,665,913	4,288,574	5,026,547
OPERATING EXPENSES:				
Sales and marketing	600,896	903,068	2,265,873	2,715,341
General and administrative	360,867	384,926	1,068,977	1,352,046
Research and development	363,652	460,765	1,067,388	1,293,645
Total operating expenses	1,325,415	1,748,759	4,402,238	5,361,032
OPERATING INCOME (LOSS)	98,100	(82,846)	(113,664)	(334,485)
Interest income (expense), net	(12,663)	37	(35,669)	(1,765)
Other income (expense), net	(52,891)	327	(179,368)	(618)
Interest expense and other expense, net	(65,554)	364	(215,037)	(2,383)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	32,546	(82,482)	(328,701)	(336,868)
Provision for income taxes				
NET INCOME (LOSS)	\$ 32,546	\$ (82,482)	\$ (328,701)	\$ (336,868)
Net income (loss) per share basic and diluted	\$ 0.00	\$ (0.01)	\$ (0.04)	\$ (0.04)
Weighted average shares basic	8,616,110	8,210,100	8,346,435	8,196,191
Weighted average shares diluted	8,619,727	8,210,100	8,346,435	8,196,191

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents**Encision Inc.****Condensed Statements of Cash Flows****(Unaudited)**

	Nine Months Ended	
	December 31, 2013	December 31, 2012
Cash flows from operating activities:		
Net loss	\$ (328,701)	\$ (336,868)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	361,040	228,497
Impairment of patent costs		42,212
Stock-based compensation expense related to stock options	44,557	46,164
Provision for doubtful accounts, net	1,000	(10,000)
Provision for inventory obsolescence, net	29,000	(72,000)
Change in operating assets and liabilities:		
Accounts receivable	(75,626)	342,080
Inventories	243,252	(61,430)
Prepaid expenses and other assets	(48,437)	(73,277)
Accounts payable	(437,437)	(346,424)
Accrued compensation and other accrued liabilities	32,671	193,818
Net cash (used in) operating activities	(178,681)	(47,228)
Cash flows from investing activities:		
Acquisition of property and equipment	(359,247)	(253,418)
Patent costs	(30,468)	(13,610)
Net cash (used in) investing activities	(389,715)	(267,028)
Cash flows from financing activities:		
Proceeds from the issuance of common stock	1,970,500	255,000
Cost of the issuance of common stock	(7,974)	(32,781)
Net cash provided by financing activities	1,962,526	222,219
Net increase (decrease) in cash and cash equivalents	1,394,130	(92,037)
Cash and cash equivalents, beginning of period	126,224	564,671
Cash and cash equivalents, end of period	\$ 1,520,354	\$ 472,634

The accompanying notes to financial statements are an integral part of these condensed statements.

Table of Contents

ENCISION INC.

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

DECEMBER 31, 2013

(Unaudited)

Note 1. ORGANIZATION AND NATURE OF BUSINESS

Encision Inc. is a medical device company that designs, develops, manufactures and markets patented surgical instruments that provide greater safety to patients undergoing minimally-invasive surgery. We believe that our patented AEM® (Active Electrode Monitoring) surgical instrument technology is changing the marketplace for electrosurgical devices and instruments by providing a solution to a patient safety risk in laparoscopic surgery. Our sales to date have been made principally in the United States.

We have an accumulated deficit of \$17,504,394 at December 31, 2013. Operating funds have been provided primarily by issuances of our common stock and warrants, a line of credit, and the exercise of stock options to purchase our common stock. Should our liquidity be diminished in the future because of operating losses, we may be required to seek additional capital in the future. Our line of credit agreement with Silicon Valley Bank is subject to renewal in May 2014. On December 17, 2013, we completed a private placement of 2,463,125 shares of our common stock. The private placement raised, before costs, a total of \$1,970,500. The purchase price per share for the shares sold in the private placement was \$0.80, representing a discount of approximately 12% based on a 20-day volume-weighted average price as of December 13, 2013. Additionally, the investors received common stock purchase warrants. The warrants are exercisable into 1,231,563 shares of the Company's common stock with an exercise price of \$1.20 per share and a term of five years.

Our strategic marketing and sales plan is designed to expand the use of our products in surgically active hospitals and surgery centers in the United States.

Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation. The condensed interim financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles accepted in the United States (GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. The condensed interim financial statements and notes thereto should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013, filed on June 28, 2013.

Edgar Filing: ENCISION INC - Form 10-Q

The accompanying condensed interim financial statements have been prepared, in all material respects, in conformity with the standards of accounting measurements and reflect, in the opinion of management, all adjustments necessary to summarize fairly the financial position and results of operations for such periods in accordance with GAAP. All adjustments are of a normal recurring nature. The results of operations for the most recent interim period are not necessarily indicative of the results to be expected for the full year.

Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. Such estimates and assumptions affect the reported amounts of assets and liabilities as well as disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expense during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents. For purposes of reporting cash flows, we consider all cash and highly liquid investments with an original maturity of three months or less to be cash equivalents.

Fair Value of Financial Instruments. Our financial instruments consist of cash and cash equivalents, short-term trade receivables and payables and a line of credit. The carrying values of cash and cash equivalents, short-term trade receivables and payables approximate their fair value due to their short maturities. The interest rate associated with the line of credit is variable and based upon fluctuations of the prime rate, thus the carrying value approximates fair value.

Concentration of Credit Risk. Financial instruments, which potentially subject us to concentrations of credit risk, consist of cash and cash equivalents, accounts receivable and a line of credit. The amount of cash on deposit with financial institutions exceeds the \$250,000 federally insured limit at December 31, 2013. We believe that cash on deposit that exceeds \$250,000 with financial institutions is financially sound and the risk of loss is minimal.

We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits.

Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The net accounts receivable balance at December 31, 2013 of \$1,060,396 included 3% from one customer. The net accounts receivable balance at March 31, 2013 of \$985,770 included 6% from one customer.

Warranty Accrual. We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is based

Table of Contents

upon historical experience and is also affected by product failure rates and material usage incurred in correcting a product failure. Should actual product failure rates or material usage costs differ from our estimates, revisions to the estimated warranty liability would be required.

Inventories. Inventories are stated at the lower of cost (first-in, first-out basis) or market. We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. At December 31, 2013 and March 31, 2013, inventory consisted of the following:

	December 31, 2013	March 31, 2013
Raw materials	\$ 1,527,924	\$ 1,843,357
Finished goods	1,209,126	1,136,945
Total gross inventories	2,737,050	2,980,302
Less reserve for obsolescence	(80,000)	(51,000)
Total net inventories	\$ 2,657,050	\$ 2,929,302

Property and Equipment. Property and equipment are stated at cost, with depreciation computed over the estimated useful lives of the assets, generally three to seven years. We use the straight-line method of depreciation for property and equipment. Leasehold improvements are depreciated over the shorter of the remaining lease term or the estimated useful life of the asset. Maintenance and repairs are expensed as incurred and major additions, replacements and improvements are capitalized.

Long-Lived Assets. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. A long-lived asset is considered impaired when estimated future cash flows related to the asset, undiscounted and without interest, are insufficient to recover the carrying amount of the asset. If deemed impaired, the long-lived asset is reduced to its estimated fair value. Long-lived assets to be disposed of are reported at the lower of their carrying amount or estimated fair value less cost to sell.

Patents. The costs of applying for patents are capitalized and amortized on a straight-line basis over the lesser of the patent's economic or legal life (20 years from the date of application in the United States). Capitalized costs are expensed if patents are not issued. We review the carrying value of our patents periodically to determine whether the patents have continuing value and such reviews could result in the conclusion that the recorded amounts have been impaired.

Income Taxes. We account for income taxes under the provisions of FASB Accounting Standards Codification (ASC) Topic 740, Accounting for Income Taxes (ASC 740). ASC 740 requires recognition of deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. ASC 740 also requires recognition of deferred tax assets for the expected future tax effects of all deductible temporary differences, loss carryforwards and tax credit carryforwards. Deferred tax assets are then reduced, if deemed necessary, by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. As a result, no provision for income tax is reflected in the accompanying statements of operations. Should we achieve sufficient, sustained income in the future, we may conclude that some or all of the valuation allowance should be reversed. We are required to make many subjective assumptions and judgments regarding our income tax exposures. At December 31, 2013, we had no unrecognized tax benefits, which would affect the effective tax rate if recognized and had no accrued interest, or penalties related to uncertain tax positions.

Edgar Filing: ENCISION INC - Form 10-Q

Revenue Recognition. Revenue from product sales is recorded when we ship the product and title has passed to the customer, provided that we have evidence of a customer arrangement and can conclude that collection is probable. Our shipping policy is FOB Shipping Point. We recognize revenue from sales to stocking distributors when there is no right of return, other than for normal warranty claims. We have no ongoing obligations related to product sales, except for normal warranty obligations. Revenue from engineering services is recognized when the service is performed.

Research and Development Expenses. We expense research and development costs for products and processes as incurred.

Stock-Based Compensation. Stock-based compensation is presented in accordance with the guidance of ASC Topic 718, Compensation - Stock Compensation (ASC 718). Under the provisions of ASC 718, companies are required to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our statements of operations.

Stock-based compensation expense recognized under ASC 718 for the three months ended December 31, 2013 and 2012 was \$16,486 and \$15,375, respectively, and for the nine months ended December 31, 2013 and 2012 was \$44,557 and \$46,164, respectively, which consisted of stock-based compensation expense related to grants of employee stock options.

Segment Reporting. We have concluded that we have one operating segment.

Recent Accounting Pronouncements. We have reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of our operations.

Note 3. BASIC AND DILUTED INCOME AND LOSS PER COMMON SHARE

We report both basic and diluted net income (loss) per share. Basic net income or loss per common share is computed by dividing net income or loss for the period by the weighted average number of common shares outstanding for the period. Diluted net income or loss per common share is computed by dividing the net income or loss for the period by the weighted average number of common and potential common shares outstanding during the period if the effect of the potential common shares is dilutive. The shares used in the calculation of dilutive potential common shares exclude options to purchase shares where the exercise price was greater than the average market price of common shares for the period.

The following table presents the calculation of basic and diluted net loss per share:

Edgar Filing: ENCISION INC - Form 10-Q

Table of Contents

	Three Months Ended		Nine Months Ended	
	December 31, 2013	December 31, 2012	December 31, 2013	December 31, 2012
Net income (loss)	\$ 32,546	\$ (82,482)	\$ (328,701)	\$ (336,868)
Weighted-average shares basic	8,616,110	8,210,100	8,346,435	8,196,191
Effect of dilutive potential common shares	3,617			
Weighted-average shares diluted	8,619,727	8,210,100	8,346,435	8,196,191
Net income (loss) per share basic	\$ 0.00	\$ (0.01)	\$ (0.04)	\$ (0.04)
Net income (loss) per share diluted	\$ 0.00	\$ (0.01)	\$ (0.04)	\$ (0.04)
Antidilutive employee stock options	617,000	502,000	627,000	502,000

Note 4. COMMITMENTS AND CONTINGENCIES

Effective December 1, 2013, we extended our noncancelable lease agreement through July 31, 2019 for our facilities at 6797 Winchester Circle, Boulder, Colorado. The lease includes \$172,176 of leasehold improvements granted by the landlord. The \$172,176 was recorded on our condensed balance sheets as leasehold improvements and deferred rent. The leasehold improvements are being amortized over the lesser of the lease term or the assets life and the deferred rent is being amortized against rent expense over the lease term. The minimum future lease payment, by fiscal year, as of December 31, 2013 is as follows:

Fiscal Year	Amount
2014 (three months remaining)	\$ 64,566
2015	260,847
2016	268,672
2017	276,732
2018	285,034
2019	293,585
2020	99,800
Total	\$ 1,549,236

Our minimum future capital equipment lease payments with General Electric Capital Corporation as of December 31, 2013, by fiscal year, are as follows:

Fiscal Year	Amount
2014 (three months remaining)	\$ 18,658
2015	76,207
2016	53,470
2017	4,283
Total	152,618
Less portion representing interest	(20,394)
Present value of minimum lease payment	132,224
Less current portion	(60,210)
	\$ 72,014

Included in our furniture, fixtures and equipment balance is leased equipment that was acquired, under the provisions of a long-term capital lease, during the quarter ended June 30, 2013. The equipment had an original cost of \$177,547 and has a net book value of \$133,115 at

Edgar Filing: ENCISION INC - Form 10-Q

December 31, 2013.

On May 10, 2012, we signed an amendment to our credit facility agreement with Silicon Valley Bank, effective May 10, 2012. The terms of the credit facility include a line of credit for \$2,000,000 for two years at an interest rate calculated at the prime rate plus 1.25%, subject to increase upon a default. Our borrowing under the credit facility is limited by our eligible receivables and inventory at the time of borrowing. The credit facility is secured by all tangible and intangible assets, whether now owned or hereafter acquired, wherever located. As of December 31, 2013, we had no borrowings from our line of credit and, under our eligible receivables and inventory limit, we had \$1,072,000 available to borrow.

Aside from the operating and capital leases, we do not have any material contractual commitments requiring settlement in the future.

We are subject to regulation by the United States Food and Drug Administration (FDA). The FDA provides regulations governing the manufacture and sale of our products and regularly inspects us and other manufacturers to determine compliance with these regulations. We believe that we were in substantial compliance with all known regulations as of December 31, 2013. FDA inspections are conducted periodically at the discretion of the FDA. Our latest inspection by the FDA occurred in December 2012.

Table of ContentsNote 5. SHARE-BASED COMPENSATION

The provisions of ASC 718-10-55 requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors, including employee stock options, based on estimated fair values. The following table summarizes stock-based compensation expense related to employee stock options and employee stock purchases for the three and nine months ended December 31, 2013 and 2012, which was allocated as follows:

	Three Months Ended		Nine Months Ended	
	December 31, 2013	December 31, 2012	December 31, 2013	December 31, 2012
Cost of sales	\$ 345	\$ 684	\$ 1,035	\$ 2,054
Sales and marketing	2,438	591	6,234	1,773
General and administrative	12,186	11,310	30,344	33,970
Research and development	1,517	2,790	6,944	8,367
Stock-based compensation expense	\$ 16,486	\$ 15,375	\$ 44,557	\$ 46,164

The Black-Scholes model requires the use of actual employee exercise behavior data and the application of a number of assumptions, including expected volatility, risk-free interest rate and expected dividends. There were 285,000 and 325,000 stock options granted during the three and nine months ended December 31, 2013, respectively. There were 89,750 and 245,000 stock options forfeited during the three and nine months ended December 31, 2013.

As of December 31, 2013, \$374,000 of total unrecognized compensation costs related to nonvested stock options is expected to be recognized over a period of five years.

Note 6. RELATED PARTY TRANSACTION

We paid consulting fees of \$18,623 and \$52,644 to an entity owned by one of our directors during the three and nine months ended December 31, 2013 and \$17,543 and \$56,355 during the three and nine months ended December 31, 2012, respectively. We paid consulting fees of \$67,161 and \$71,152 to an entity owned by our Executive Chairman during the three and nine months ended December 31, 2013, respectively, and \$5,465 and \$77,072 during the three and nine months ended December 31, 2012, respectively.

Note 7. RECENT DEVELOPMENTS

Effective December 1, 2013, we extended our noncancelable lease agreement for our facilities at 6797 Winchester Circle, Boulder, Colorado through July 31, 2019.

Edgar Filing: ENCISION INC - Form 10-Q

On December 17, 2013, we completed a private placement of 2,463,125 shares of our common stock. The private placement raised, before costs, a total of \$1,970,500. The purchase price per share for the shares sold in the private placement was \$0.80, representing a discount of approximately 12% based on a 20-day volume-weighted average price as of December 13, 2013. Additionally, the investors received common stock purchase warrants. The warrants are exercisable into 1,231,563 shares of the Company's common stock with an exercise price of \$1.20 per share and a term of five years. The fair value of the warrants, \$568,810, was estimated at the date of the grant using the Black-Scholes option pricing model, with an allocation of the proceeds applied to the warrants. The difference between the warrant allocation and the proceeds was allocated to the shares of common stock issued. The fair value of the warrants of \$568,810 has been included in the total additional paid-in capital value of \$1,970,500 on the Condensed Balance Sheets. The following assumptions were used in the Black-Scholes pricing model:

Expected life (in years)	5
Volatility	91.00%
Risk-free interest rate	1.50%
Dividend yield (on common stock)	0.00%

Note 8. SUBSEQUENT EVENTS

We evaluated all of our activity and concluded that no subsequent events have occurred that would require recognition in our financial statements or disclosed in the notes to our financial statements.

Table of Contents

ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Certain statements contained in this section on Management's Discussion and Analysis are not historical facts, including statements about our strategies and expectations with respect to new and existing products, market demand, acceptance of new and existing products, marketing efforts, technologies and opportunities, market and industry segment growth, and return on investments in products and markets. These statements are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward looking statements. All forward looking statements in this section on Management's Discussion and Analysis are based on information available to us on the date of this document, and we assume no obligation to update such forward looking statements. Readers of this Form 10-Q are strongly encouraged to review the section entitled *Risk Factors* in our Form 10-K for the fiscal year ended March 31, 2013.

General

Encision Inc., a medical device company based in Boulder, Colorado, has developed and markets innovative technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. We believe that our patented Active Electrode Monitoring (AEM®) Surgical Instruments are changing the marketplace for electrosurgical devices and laparoscopic instruments by providing a solution to a well-documented hazard unique to laparoscopic surgery. The Center for Medicare and Medicaid Services (CMS) recently published its Hospital-Acquired Condition Reduction Program effective October 1, 2014. At that time, the program will begin to levy as much as a 1% penalty on Medicare reimbursements on hospitals in the lower quadrant of performance for selected quality indicators, including accidental puncture and laceration (APL). Examples of APL include the use of a cautery device (electrosurgery) or scissors to dissect a tissue plane that errantly causes an injury to underlying bowel.

We address market opportunities created by the increase in minimally-invasive surgery (MIS) and surgeons' use of electrosurgery devices in these procedures. The product opportunity exists in that monopolar electrosurgery instruments used in laparoscopic procedures provide excellent clinical results, but are also susceptible to causing inadvertent collateral tissue damage outside the surgeon's field of view due to insulation failure and capacitive coupling. The risk of unintended electrosurgical burn injury to the patient in laparoscopic surgery has been well documented. This risk poses a threat to patient safety, including the risk of death, and creates liability exposure for surgeons and hospitals, as well as increased and preventable readmissions.

Our patented AEM technology provides surgeons with the desired tissue effects, while preventing stray electrosurgical energy that can cause unintended and unseen tissue injury that may result in death. AEM Surgical Instruments are equivalent to conventional instruments in size, shape, ergonomics, functionality and competitive pricing, but they incorporate Active Electrode Monitoring technology to dynamically and continuously monitor the flow of electrosurgical current, thereby helping to prevent patient injury. With our shielded and monitored instruments, surgeons are able to perform electrosurgical procedures more safely, effectively and economically than is possible using conventional instruments or alternative energy sources.

AEM technology has been recommended and endorsed by many groups involved in MIS. Surgeons, nurses, biomedical engineers, the medicolegal community, malpractice insurance carriers and electrosurgical device manufacturers advocate the use of AEM technology. We have focused our marketing strategies to date on expanding the market awareness of the AEM technology and our broad independent endorsements and have continued efforts to improve and expand the AEM technology penetration. In our second quarter that ended December 31, 2013, AEM procedural volume was 21,700 procedures using AEM Technology as compared to 23,200 procedures for the same period one year ago.

When a hospital or surgery center changes to AEM technology, we receive recurring revenue from sales of replacement instruments. We believe that there is no directly competing technology to supplant AEM products. The replacement market of reusable and disposable AEM products in hospitals and surgery centers that use our AEM technology represented over 90% of our product revenue during the three months ended December 31, 2013. This revenue stream is expected to grow as the base of accounts that switch to AEM technology grows. In addition, we intend to further develop disposable versions of more of our AEM products in order to meet market demands and expand our sales opportunities.

We have an accumulated deficit of \$17,504,394 at December 31, 2013. Operating funds have been provided primarily by issuances of our common stock and warrants, a line of credit, and the exercise of stock options to purchase our common stock. Should our liquidity be diminished in the future because of operating losses, we may be required to seek additional capital in the future. Our line of credit agreement with Silicon Valley Bank is subject to renewal in May 2014.

During the nine months ended December 31, 2013, we used \$178,681 of cash from our operations and used \$359,247 for investments in property and equipment. As of December 31, 2013, we had \$1,520,354 in cash and cash equivalents available to fund future operations, an increase of \$1,394,130 from March 31, 2013. On December 17, 2013, we completed a private placement of 2,463,125 shares of our common stock. The private placement raised, before costs, a total of \$1,970,500, which was partially used to paydown our line of credit. Our working capital was \$4,202,991 at December 31, 2013 compared to \$2,518,553 at March 31, 2013.

Historical Perspective

We were organized in 1991 and spent several years developing the AEM monitoring system and protective sheaths to adapt to conventional electrosurgical instruments. We have invested heavily in an effort to protect our valuable technology, and, as a result of this effort, we have been issued nine unexpired relevant patents that together form a significant intellectual property position. Our patents relate to the basic shielding and monitoring technologies that we incorporate into our AEM products. As of December 31, 2013, we have nine unexpired United States patents relating to specific implementations of shielding and monitoring in instruments.

Table of Contents

Our AEM Surgical Instruments have been engineered to provide a seamless transition for surgeons switching from conventional laparoscopic instruments. AEM technology has been integrated into instruments that have the same look, feel and functionality as conventional instruments that surgeons have been using for years. The AEM product line encompasses the full range of instrument sizes, types and styles favored by surgeons. Additionally we continued to improve quality and add to the product line. These additions include more disposable versions, the introduction of hand-activated instruments, our enhanced scissors, the e Edge scissors, and the EM3 AEM Monitor. Hospitals can make a complete and smooth conversion to our product line, thereby advancing patient safety in MIS.

Outlook

Installed Base of AEM Monitoring Equipment: We believe that sales of our installed base of AEM products will increase sales as the inherent risks associated with monopolar laparoscopic electrosurgery become more widely acknowledged, as we focus on increasing our sales efficiency and with recent quality enhancement to our product line. We expect that the replacement sales of electrosurgical instruments and accessories will also increase as additional facilities adopt AEM technology. We anticipate that the efforts to improve the productivity of sales representatives carrying the AEM product line, along with the introduction of next generation products, may provide the basis for increased sales and profitable operations. However, these measures, or any others that we may adopt, may not result in either increased sales or profitable operations.

We believe that the unique performance of the AEM technology and our breadth of independent endorsements provide an opportunity for continued market share growth. In our view, market awareness and awareness of the clinical credibility of the AEM technology, as well as awareness of our endorsements, are improving, and we expect this awareness to benefit our sales efforts for the remainder of fiscal year 2014. Our objectives in the remainder of fiscal year 2014 are to optimize sales execution, to expand market awareness of the AEM technology and to maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers. In addition, acceptance of AEM products depends on surgeons preference for our instruments, which depends on factors such as ergonomics, quality and ease of use in addition to the technological and safety advantages of AEM products. If surgeons prefer other instruments to our instruments, our business results will suffer.

In March 2010, the Patient Protection and Affordable Care Act was enacted in the United States. This legislation includes a provision that imposes a 2.3% excise tax on the sale of certain medical devices by a manufacturer, producer or importer of such devices in the United States starting after December 31, 2012. Most of our product revenue will be subject to the tax. We expense the medical device tax in other income and expense.

Possibility of Operating Losses: We have an accumulated deficit of \$17,504,394 at December 31, 2013. Operating funds have been provided primarily by issuances of our common stock and warrants, and the exercise of stock options to purchase our common stock. Should our liquidity be diminished in the future because of operating losses, we may be required to seek additional capital. We have made strides toward improving our operating results but due to the ongoing need to develop, optimize and train our direct sales managers and the independent sales representative network, the need to support the development of refinements to our product line, and the need to increase sustained sales to a level adequate to cover fixed and variable operating costs, we may operate at a net loss. Sustained losses, or our inability to generate sufficient cash flow from operations to fund our obligations, may result in a need to raise additional capital.

Revenue Growth: We expect to generate increased product revenue in the U.S. from sales to new customers and from expanded sales to existing customers as the medical device industry stabilizes and our network of direct and independent sales representatives becomes more efficient. We believe that the visibility and credibility of the independent clinical endorsements for AEM technology will contribute to new accounts and increased product revenue in fiscal year 2014. We also expect to increase market share through promotional programs of placing our AEM monitors at no charge into hospitals that commit to standardize with AEM instruments. However, all of these efforts to increase market share

Edgar Filing: ENCISION INC - Form 10-Q

and grow product revenue will depend in part on our ability to expand the efficiency and effective coverage range of our direct and independent sales representatives, as well as maintain and in some cases, improve the quality of our product offerings. Service revenue represents design, development and product supply revenue from our agreements with strategic partners.

We also have longer term initiatives in place to improve our prospects. We expect that development of next generation versions of our AEM products will better position our products in the marketplace and improve our retention rate at hospitals and surgery centers that have changed to AEM technology, enabling us to grow our sales. We are exploring overseas markets to assess opportunities for sales growth internationally. Finally, we intend to explore opportunities to capitalize on our proven AEM technology via licensing arrangements and strategic alliances. These efforts to generate additional sales and further the market penetration of our products are longer term in nature and may not materialize. Even if we are able to successfully develop next generation products or identify potential international markets or strategic partners, we may not be able to capitalize on these opportunities.

Gross Profit and Gross Margins: Gross profit and gross margins can be expected to fluctuate from quarter to quarter as a result of product sales mix, sales volume and service revenue. Gross margins on products manufactured or assembled by us are expected to improve at higher levels of production and sales.

Sales and Marketing Expenses: We continue to refine our domestic and international distribution capability, and we believe that sales and marketing expenses will decrease as a percentage of net sales with increasing sales volume.

Research and Development Expenses: Research and development expenses are expected to increase to support quality improvement efforts and development of refinements to our AEM product line and new products, which will further expand options for surgeons and hospitals.

Results of Operations

For the three months ended December 31, 2013 compared to the three months ended December 31, 2012.

Product Revenue. Product revenue for the quarter ended December 31, 2013 was \$2,643,757 compared to \$2,954,849 for the quarter ended December 31, 2012, a decrease of 10.5%. The decrease of product revenue is attributable to business lost from accounts that stopped using AEM technology and to other cost-reduction factors, including, but not limited to, using alternatives to AEM products, using less AEM products, and using outside reproprocessors who reprocess our products for resale. This was partially offset by one new hospital accounts that we opened for AEM technology, which increased the

Edgar Filing: ENCISION INC - Form 10-Q

Table of Contents

installed base of users of reusable and disposable AEM Surgical Instruments, in the three months ended December 31, 2013 versus nine new accounts for AEM technology in the three months ended December 31, 2012.

Service Revenue. Service revenue for the quarter ended December 31, 2013 was \$71,748 compared to \$99,831 for the quarter ended December 31, 2012, a decrease of \$28,083. Service revenue represents design, development and product supply services.

Gross profit. Product gross profit for the quarter ended December 31, 2013 of \$1,398,437 represented a decrease of 14% from gross profit of \$1,637,887 for the quarter ended December 31, 2012. Gross profit as a percentage of sales (gross margins) decreased from 55% for the quarter ended December 31, 2012 to 53% for the quarter ended December 31, 2013. The decrease in gross margins in the quarter ended December 31, 2013 was the result of the increase in overhead costs per unit of product due to decreased volume of product.

Service gross profit for the quarter ended December 31, 2013 of \$25,078 represented a decrease of \$2,948 from \$28,026 for the quarter ended December 31, 2012.

Sales and marketing expenses. Sales and marketing expenses of \$600,896 for the quarter ended December 31, 2013 represented a decrease of 33% from sales and marketing expenses of \$903,068 for the quarter ended December 31, 2012. The decrease was the result of reduced compensation as a result of a reduced number of direct sales representatives, reduced trade show costs, sales samples, and travel and meals. The decrease in expense was partially offset by increased commissions for increased independent sales representatives.

General and administrative expenses. General and administrative expenses of \$360,867 for the quarter ended December 31, 2013 represented a decrease of 6% from general and administrative expenses of \$384,926 for the quarter ended December 31, 2012. The decrease was the result of reduced compensation and bonus accrual. The decrease in expense was partially offset by increased outside services.

Research and development expenses. Research and development expenses of \$363,652 for the quarter ended December 31, 2013 represented a decrease of 21% compared to \$460,765 for the quarter ended December 31, 2012. The decrease was the result of decreased temporary help and inventory usage, and higher patent application expense in last year's quarter. The decrease in expense was partially offset by an increase in test and prototype materials cost.

Other income and expense, net. Other income and expense, net includes \$58,679 for the medical device excise tax for the quarter ended December 31, 2013 and none for the quarter ended December 31, 2012.

Net income. Net income was \$32,546 for the quarter ended December 31, 2013 compared to net loss of \$82,482 for the quarter ended December 31, 2012. Net income was a result of significantly lower operating expenses. Net income was partially reduced by lower product and service revenue, lower gross profit margin, and the medical device excise tax.

Edgar Filing: ENCISION INC - Form 10-Q

For the nine months ended December 31, 2013 compared to the nine months ended December 31, 2012.

Product Revenue. Product revenue for the nine months ended December 31, 2013 was \$7,851,755 compared to \$8,566,008 for the nine months ended December 31, 2012, a decrease of 8%. The decrease of product revenue is attributable to business lost from accounts that stopped using AEM technology and to other cost-reduction factors, including, but not limited to, using alternatives to AEM products, using less AEM products, and using outside reproducers who reprocess our products for resale. The decrease was partially offset by ten new hospital accounts that we opened for AEM technology, which increased the installed base of users of reusable and disposable AEM Surgical Instruments, in the nine months ended December 31, 2013 and twenty new hospital accounts in the nine months ended December 31, 2012.

Service Revenue. Service revenue for the nine months ended December 31, 2013 was \$191,063 compared to \$463,835 for the nine months ended December 31, 2012, a decrease of \$272,772. The decrease is a result of a project that had been phased out by a strategic partner. Service revenue represents design, development and product supply services.

Gross profit. Product gross profit for the nine months ended December 31, 2013 of \$4,216,328 represented a decrease of 13% from gross profit of \$4,874,284 for the nine months ended December 31, 2012. Gross profit as a percentage of sales (gross margins) decreased from 57% for the nine months ended December 31, 2012 to 54% for the nine months ended December 31, 2013. The decrease in gross margins in the nine months ended December 31, 2013 was the result of the increase in overhead costs per unit of product due to decreased volume of product.

Service gross profit for the nine months ended December 31, 2013 of \$72,246 represented a decrease of \$80,017 from \$152,263 for the nine months ended December 31, 2012.

Sales and marketing expenses. Sales and marketing expenses of \$2,265,873 for the nine months ended December 31, 2013 represented a decrease of 17% from sales and marketing expenses of \$2,715,341 for the nine months ended December 31, 2012. The decrease was the result of reduced compensation as a result of a reduced number of direct sales representatives, elimination of a sales meeting and reduced travel and meals. The decrease in expense was partially offset by increased commissions for increased independent sales representatives, sales samples and promotion costs, and trade shows.

General and administrative expenses. General and administrative expenses of \$1,068,977 for the nine months ended December 31, 2013 represented a decrease of 28% from general and administrative expenses of \$1,352,046 for the nine months ended December 31, 2012. The decrease was the result of reduced compensation and bonus accrual, legal costs and training software.

Research and development expenses. Research and development expenses of \$1,067,388 for the nine months ended December 31, 2013 represented a decrease of 17% compared to \$1,293,645 for the nine months ended December 31, 2012. The decrease was the result of decreased temporary help and outside services, inventory usage, and higher patent application expense in last year's quarter. The decrease in expense was partially offset by an increase in compensation, especially for quality efforts and development of new products, increased test and prototype materials, and reduced internal resource cost allocation to service revenue cost of revenue due to reduced service revenue.

Other income and expense, net. Other income and expense, net includes \$178,919 for the medical device excise tax for the nine months ended December 31, 2013 and none for the nine months ended December 31, 2012.

Table of Contents

Net loss. Net loss was \$328,701 for the nine months ended December 31, 2013 compared to net loss of \$336,868 for the nine months ended December 31, 2012. Net loss was a result of lower product and service revenue, and the lower gross profit thereon, and the medical device excise tax. Net loss was partially reduced by significantly lower operating expenses.

The results of operations for the three and nine months ended December 31, 2013 are not indicative of the results of operations for all or any part of the balance of the fiscal year.

Liquidity and Capital Resources

To date, operating funds have been provided primarily by issuances of our common stock and warrants, the exercise of stock options to purchase our common stock and, in some years, by operating profits. Common stock and additional paid in capital totaled \$23,577,078 from our inception through December 31, 2013. On December 17, 2013, we completed a private placement of 2,463,125 shares of our common stock. The private placement raised, before costs, a total of \$1,970,500.

On May 10, 2012, we signed an amendment to our credit facility agreement with Silicon Valley Bank, effective May 10, 2012. The terms of the credit facility include a line of credit for \$2,000,000 for two years at an interest rate calculated at the prime rate plus 1.25%, subject to increase upon a default. Our borrowing under the credit facility is limited by our eligible receivables and inventory at the time of borrowing. The credit facility is secured by all tangible and intangible assets, whether now owned or hereafter acquired, wherever located. As of December 31, 2013, we had no borrowings from our line of credit and, under our eligible receivables and inventory limit, we had \$1,072,000 available to borrow.

Our operations used \$178,681 of cash during the nine months ended December 31, 2013 on net revenue of \$7,851,755. Cash was used, principally, by our net loss and decreased accounts payable, and was partially offset by decreased inventories. The amounts of cash used by operations for the nine months ended December 31, 2013 are not indicative of the expected amounts of cash to be generated from or used in operations in fiscal year 2014. During the nine months ended December 31, 2013, we invested \$359,247 in the acquisition of property and equipment. As of December 31, 2013, we had \$1,520,354 in cash and cash equivalents available to fund future operations. Working capital was \$4,202,991 at December 31, 2013 compared to \$2,518,553 at March 31, 2013. The increase to working capital at December 31, 2013 was the result, principally, of a private placement of 2,463,125 shares of our common stock. The private placement raised, before costs, a total of \$1,970,500. The increase was partially reduced by our paydown of our line of credit. Current liabilities were \$1,144,770 at December 31, 2013, compared to \$1,588,634 at March 31, 2013. The decrease in current liabilities at December 31, 2013 was principally caused by a decrease to accounts payable and other accrued liabilities.

Effective December 1, 2013, we extended our noncancelable lease agreement through July 31, 2019 for our facilities at 6797 Winchester Circle, Boulder, Colorado. The lease includes \$172,176 of leasehold improvements granted by the landlord. The \$172,176 was recorded on our condensed balance sheets as leasehold improvements and deferred rent. The leasehold improvements are being amortized over the lesser of the lease term or the assets life and the deferred rent is being amortized against rent expense over the lease term. The minimum future lease payment, by fiscal year, as of December 31, 2013 is as follows:

Fiscal Year	Amount
2014 (three months remaining)	\$ 64,566

Edgar Filing: ENCISION INC - Form 10-Q

2015		260,847
2016		268,672
2017		276,732
2018		285,034
2019		293,585
2020		99,800
Total	\$	1,549,236

Our minimum future capital equipment lease payments with General Electric Capital Corporation as of December 31, 2013, by fiscal year, are as follows:

Fiscal Year	Amount
2014 (three months remaining)	\$ 18,658
2015	76,207
2016	53,470
2017	4,283
Total	152,618
Less portion representing interest	(20,394)
Present value of minimum lease payment	132,224
Less current portion	(60,210)
	\$ 72,014

As of December 31, 2013, the following table shows our contractual obligations for the periods presented:

Contractual obligations	Totals	Payment due by period			
		Less than 1 year	1-3 years	3-5 years	More than 5 years
Operating lease obligations	1,701,854	336,015	617,167	575,477	173,196

Table of Contents

Aside from the operating leases and credit facility commitments, we do not have any material contractual commitments requiring settlement in the future.

Our fiscal year 2014 operating plan is focused on increasing new accounts, retaining existing customers, growing revenue, increasing gross profits and conserving cash. We are investing in research and development efforts to develop next generation versions of the AEM product line. We have invested in manufacturing property and equipment to manufacture disposable scissors inserts internally and to reduce our cost of product revenue. We cannot predict with certainty the expected revenue, gross profit, net income or loss and usage of cash and cash equivalents for fiscal year 2014. On May 10, 2012, we signed an amendment to our credit facility agreement with Silicon Valley Bank, effective May 10, 2012. The terms of the credit facility include a line of credit for \$2,000,000 for two years at an interest rate calculated at the prime rate plus 1.25%, subject to increase upon a default. Our borrowing under the credit facility is limited by our eligible receivables and inventory at the time of borrowing. We believe that our cash resources and credit facility will be sufficient to fund our operations for at least the next twelve months. If we are unable to manage our business operations in line with budget expectations, it could have a material adverse effect on our business viability, financial position, results of operations and cash flows.

Income Taxes

As of March 31, 2013, net operating loss carryforwards totaling approximately \$7.7 million are available to reduce taxable income in the future. The net operating loss carryforwards expire, if not previously utilized, at various dates beginning in the fiscal year ending March 31, 2019. We have not paid income taxes since our inception. The Tax Reform Act of 1986 and other income tax regulations contain provisions which may limit the net operating loss carryforwards available to be used in any given year if certain events occur, including changes in ownership interests. We have established a valuation allowance for the entire amount of our deferred tax asset since inception due to our history of losses. Should we achieve sufficient, sustained income in the future, we may conclude that some or all of the valuation allowance should be reversed. If some or all of the valuation allowance were reversed, then, to the extent of the reversal, a tax benefit would be recognized which would result in an increase to net income.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, sales and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to bad debts, inventories, sales returns, warranty, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our financial statements.

We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances would be required, which would increase our expenses during the periods in which any such allowances were made. The amount recorded as a provision for bad debts in each period is based upon our assessment of the likelihood that we will be paid on our outstanding receivables, based on customer-specific as well as general considerations. To the extent that our estimates prove to be too high, and we ultimately collect a receivable previously determined to be impaired, we may record a reversal of the provision in the period of such determination.

We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, we have experienced some costs related to warranties. The warranty accrual is based on historical experience and is adjusted based on current experience. Should actual warranty experience differ from our estimates, revisions to the estimated warranty liability would be required.

We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based on assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. Any write-downs of inventory would reduce our reported net income during the period in which such write-downs were applied. To the extent that our estimates prove to be too high, and we ultimately utilize or sell inventory previously determined to be impaired, we may record a reversal of the provision in the period of such determination.

We recognize deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are then reduced, if deemed necessary, by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. Should we maintain sufficient, sustained income in the future, we may conclude that all or some of the valuation allowance should be reversed.

Property and equipment are stated at cost, with depreciation computed over the estimated useful lives of the assets, generally three to seven years. We use the straight-line method of depreciation for property and equipment. Leasehold improvements are depreciated over the shorter of the remaining lease term or the estimated useful life of the asset. Maintenance and repairs are expensed as incurred and major additions, replacements and improvements are capitalized.

We amortize our patent costs over their estimated useful lives, which is typically the remaining statutory life. From time to time, we may be required to adjust these useful lives of our patents based on advances in technology, competitor actions, and the like. We review the recorded amounts of patents at each period end to determine if their carrying amount is still recoverable based on our expectations regarding sales of related products. Such an assessment, in the future, may result in a conclusion that the assets are impaired, with a corresponding charge against earnings.

Table of Contents

We currently estimate forfeitures for stock-based compensation expense related to employee stock options at 23% and evaluate the forfeiture rate quarterly. Other assumptions that are used in calculating stock-based compensation expense include risk-free interest rate, expected life, expected volatility and expected dividend.

Table of Contents

ITEM 4 CONTROLS AND PROCEDURES

(a) We have carried out an evaluation under the supervision and with the participation of our management, including our President and CEO and Principal Accounting and Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange Act of 1934 (the Exchange Act)). Based upon that evaluation, the President and CEO and the Principal Accounting and Financial Officer concluded that, as of December 31, 2013, our disclosure controls and procedures were effective.

(b) During the quarter ended December 31, 2013, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. **OTHER INFORMATION**

ITEM 6 **Exhibits**

The following exhibits are filed with this report on Form 10-Q or are incorporated by reference:

4.1 Form of Warrant (attached as Exhibit B to the Securities Purchase Agreement filed below as Exhibit 10.1)

10.1 Securities Purchase Agreement dated December 17, 2013 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on December 23, 2013)

10.2 Registration Rights Agreement dated December 17, 2013(incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on December 23, 2013)

10.3 Employment Agreement, dated December 17, 2013, between Encision Inc. and Gregory J. Trudel (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed on December 23, 2013)

31.1 Certification of President and CEO under Rule 13a-14(a) of the Exchange Act (filed herewith).

31.2 Certification of Principal Financial and Accounting Officer under Rule 13a-14(a) of the Exchange Act (filed herewith).

32.1 Certifications of President and CEO and Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

101 The following materials from Encision Inc. s Quarterly Report on Form 10-Q for the quarter ended December 31, 2013, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Balance Sheets, (ii) the unaudited Condensed Statements of Income, (iii) the unaudited Condensed Statements of Cash Flows, and (iv) Notes to Condensed Financial Statements, tagged at Level I.

Edgar Filing: ENCISION INC - Form 10-Q

Users of the XBRL data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Encision Inc.

February 11, 2014
Date

/s/ Mala Ray
Mala Ray
Controller
Principal Accounting Officer &
Principal Financial Officer